Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
CAMBRIDGE, Mass., May 04, 2018 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, May 10, 2018 at 9:00 a.m. ET to discuss financial results for the first quarter of 2018. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 3866939. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.
Contact:
Jennifer LaVin
617-715-6687
[email protected]
